hostdirect
therapi
network
consortium
ebola
viru
inhibit
mapk
experiment
pyridinyl
imidazol
compound
ie
abolish
ebola
viru
entri
thu
replic
primari
human
dendrit
cell
dc
concomit
reduc
product
proinflammatori
cytokin
includ
rant
dengu
viru
denvinduc
secret
proinflammatori
mediat
infect
myeloidderiv
cell
shown
downregul
via
pharmacolog
inhibit
mapk
experiment
drug
furthermor
mice
first
infect
denv
treat
experiment
mapk
inhibitor
exhibit
reduc
vasculopathi
intestin
haemorrhag
enteroviru
mapk
also
shown
induc
tnfa
dc
infect
enteroviru
pharmacolog
abrog
treatment
sepsi
regard
common
caus
death
among
newborn
global
least
death
report
annual
basi
gramneg
bacteria
ie
staphylococci
enterococci
klebsiella
sp
escherichia
coli
neisseria
sp
pseudomonad
frequent
associ
infant
death
due
sepsi
case
sever
clinic
studi
report
date
mortal
due
sepsi
larg
due
aberr
immun
reaction
patient
collect
known
system
inflammatori
respons
syndrom
sir
result
septic
shock
mark
interplay
proand
antiinflammatori
host
factor
combin
cellular
exhaust
present
clinic
manag
sepsi
reli
antibiot
larg
compris
ampicillin
penicillin
combin
gentamicin
infant
age
month
infant
older
month
benzylpenicillin
plu
chloramphenicol
use
clinic
case
suspect
sepsi
due
staphylococc
infect
combin
flucloxacilin
thirdgener
antibiot
administ
although
latter
becom
mainstay
treatment
mani
develop
countri
due
low
cost
thirdgener
cephalosporin
also
use
drugresist
infect
caus
sepsi
howev
resist
type
chemotherapeut
agent
current
clinic
practic
sepsi
treatment
frequent
report
hostdirect
clinic
measur
attempt
adjunct
standard
antibiot
therapi
sepsi
manag
clinic
ibuprofen
therapi
although
success
reduc
pyrogen
patient
sepsi
downregul
thromboxan
prostaglandin
product
result
improv
surviv
high
level
detect
sera
patient
sir
concomit
sever
sepsi
diseas
prior
use
atorvastatin
patient
sepsi
manifest
lower
baselin
level
serum
concomit
shorter
hospit
stay
better
surviv
random
control
trial
statinna
patient
hospit
sepsi
show
inpati
atorvastatin
mg
per
day
reduc
progress
sever
sepsi
control
patient
vs
treat
patient
p
extens
review
treatment
patient
septic
shock
trend
toward
improv
surviv
notic
among
patient
high
level
circul
addit
reflect
gener
reduct
overal
allcaus
mortal
blockad
receptor
recombin
human
antagonist
anakinra
result
signific
improv
allcaus
mortal
patient
sever
sepsi
newer
strategi
aim
reduc
mortal
focuss
modul
host
physiolog
pathway
involv
secret
inflammatori
cytokin
pharmacolog
reduct
use
glyburid
cholesterol
metabol
administ
recombin
highdens
lipoprotein
tcell
exhaust
target
pathway
use
recombin
antibodi
sialic
acid
glycan
residu
ubiquit
biolog
system
mammal
sialic
acid
integr
compon
sever
cellular
receptor
particip
gener
physiolog
homeostasi
influenza
viru
easili
target
host
cell
express
sialic
acidcontain
receptor
entri
replic
cleavag
motif
use
sialidasebas
agent
ie
would
contribut
dramat
reduct
viral
load
besid
influenza
myriad
pathogen
includ
limit
vibrio
cholera
clostridium
tetani
merscov
h
pylori
also
use
sialic
acidcontain
receptor
initi
pathogenesi
human
either
cell
entri
toxin
uptak
immun
suppress
receptor
therefor
present
highli
attract
target
hostdirect
therapi
one
receptor
host
receptor
merscov
entri
alreadi
discuss
earlier
review
target
current
use
antidiabet
drug
sitagliptin
vildagliptin
mitogenactiv
protein
kinas
mapk
key
enzym
particip
crucial
biochem
process
eukaryot
cell
rang
cell
prolifer
apoptosi
among
variou
mapk
enzym
exist
mapk
particular
import
infect
biolog
owe
involv
cytokin
signal
includ
apoptosi
autophagi
sever
hostdirect
intervent
target
inhibit
activ
mapk
report
variou
infecti
diseas
inhibit
mapk
shown
protect
mice
lethal
infect
avian
influenza
viru
infect
via
dampen
proinflammatori
cytokin
product
ultim
manifest
extens
surviv
tb
suppress
product
cell
shown
direct
effect
tb
mapk
upregul
pharmacolog
inhibit
mapk
activ
help
restor
abil
cell
secret
respons
antigen
stimul
later
shown
pharmacolog
blockad
egfr
use
gefitinib
concomitantli
abolish
mapk
activ
tbinfect
cell
consequ
kill
intracellular
bacteria
via
autophagi
subsequ
preclin
valid
phenotyp
result
reduc
tb
prolifer
lung
infect
mice
mapk
inhibit
could
therefor
viabl
strategi
control
excess
inflamm
tissu
destruct
cours
progress
tb
diseas
blastocysti
infect
protozoan
parasit
blastocysti
sp
infect
implic
pathogenesi
inflammatori
bowel
diseas
human
murin
model
primari
blastocysti
infect
induct
mapk
express
pathogen
shown
trigger
releas
proinflammatori
cytokin
pharmacolog
inhibit
mapk
result
reduc
product
particularli
highlight
central
role
play
enzym
diseas
progress
aryl
hydrocarbon
receptor
ahr
long
known
host
molecul
detect
respond
environment
toxin
polycycl
dioxin
newlydescrib
role
pathogen
recognit
receptor
affin
pigment
moieti
seem
play
import
protect
role
infect
pseudomona
aeruginosa
tb
plasmodium
berghei
listeria
monocytogen
major
intracellular
pathogen
perhap
activ
ahr
latent
infect
prophylaxi
use
dioxinlik
particl
nonetheless
nonpatholog
might
clinic
benefit
time
import
ascertain
biolog
process
induc
product
kynurenin
upregul
sinc
may
oncogen
ahrdepend
manner
complement
pathway
repres
highli
import
arm
innat
immun
respons
thu
constitut
crucial
defenc
mechan
intracellular
extracellular
pathogen
clinic
assess
antibacteri
vaccin
biolog
serum
bactericid
assay
sba
use
gaug
antigenspecif
complementdepend
kill
pathogen
bacteria
although
use
complement
protein
hostdirect
administr
antibodybind
complement
protein
patient
may
enhanc
pathogenicspecif
antibodi
activ
control
infect
diseas
larg
nevertheless
novel
therapeut
peptid
deriv
ctermin
complement
protein
involv
format
membran
attack
complex
surfac
bacteria
evalu
group
b
streptococcu
gb
methicillinresist
staphylococcu
aureu
mrsa
infect
mice
mous
model
dermonecrosi
treatment
appear
reduc
gb
load
vagin
tract
show
direct
bactericid
effect
cocci
mrsainfect
mice
subcutan
treatment
result
reduct
skin
lesion
size
bacteri
load
coupl
increas
neutrophil
infiltr
amelior
diseas
vital
lipid
mediat
circul
mainli
blood
biosynthesis
via
enzymat
activ
sphingosin
kinas
signal
via
implic
varieti
biolog
process
includ
lymphocyt
traffick
cholesterol
metabol
angiogenesi
among
other
importantli
activ
pathway
may
improv
egress
antigenspecif
b
cell
lymphat
compart
tissu
control
infect
recent
publish
studi
reveal
pharmacolog
induct
releas
activ
murin
infect
bordetella
pertussi
result
decreas
lung
tissu
patholog
accompani
reduct
bacteri
load
also
shown
mous
model
cryptococcu
neoforman
infect
addit
exogen
mice
defici
promot
earli
neutrophil
influx
lung
contribut
format
hostprotect
granuloma
might
also
relev
prevent
mrsainduc
dermanecrosi
transfer
rna
trna
crucial
transport
newli
synthesis
singlestrand
mrna
ribosom
translat
protein
irrevers
abrog
process
may
effect
lead
cell
death
target
trna
synthetas
discuss
potenti
target
direct
therapi
prokaryot
eukaryot
initi
studi
use
borrelidin
polyketid
deriv
streptomyc
sp
capabl
select
inhibit
activ
threonyl
trna
synthetas
p
falciparum
brucei
well
acut
lymphoblast
leukaemia
cell
valid
blockad
trna
synthesi
promis
druggabl
target
clinic
translat
transmembran
coreceptor
bind
variou
receptor
tyrosin
kinas
vascular
endotheli
growth
factor
receptor
vegfr
transform
growth
factor
beta
receptor
plexin
vegf
semaphorin
heparin
glycan
bind
receptor
complex
initi
signal
cascad
promot
angiogenesi
neural
system
develop
cell
adhes
also
shed
cell
thu
detect
serum
although
strongli
associ
regulatori
cell
treg
mice
rather
marker
activ
human
cell
addit
absenc
human
treg
express
reflect
poor
prognosi
lung
prostat
colon
pancreat
breast
cancer
led
develop
therapeut
target
inaugur
clinic
trial
mab
advanc
solid
tumour
includ
lung
pancreat
crc
publish
display
good
safeti
profil
patient
coadministr
bevacizumab
antivegf
also
clinic
investig
patient
advanc
solid
tumour
reconsider
standard
bevacizumab
dose
requir
given
combin
pertain
infecti
diseas
associ
promot
liver
cirrhosi
patient
hcv
infect
enhanc
ebv
entri
human
nasopharyng
epitheli
cell
well
htlvdriven
syncytia
format
human
cell
find
warrant
investig
hdt
target
human
infecti
diseas
